Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?
INVESTIGATING
The domain expert identified p-tau217 as the most clinically viable threshold marker, but its validation as a stopping rule requires prospective studies. This directly addresses the clinical practice gap identified in the source paper.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab)
Landscape Summary:
Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds? is a 0.88 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: investigating.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds? — INVOKE-2 (completed)